Rozlytrek (entrectinib) — Medica
Pediatric diffuse high-grade gliomas (NTRK gene fusion-positive)
Initial criteria
- age < 18 years
- tumor is positive for NTRK gene fusion
- medication is used as adjuvant therapy OR medication is used for recurrent or progressive disease
Approval duration
1 year